Last reviewed · How we verify
lorcaserin + phentermine-HCl
This combination uses lorcaserin (a 5-HT2C receptor agonist) to reduce appetite and phentermine (a sympathomimetic amine) to increase energy expenditure and suppress appetite for weight management.
This combination uses lorcaserin (a 5-HT2C receptor agonist) to reduce appetite and phentermine (a sympathomimetic amine) to increase energy expenditure and suppress appetite for weight management. Used for Chronic weight management in adults with obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | lorcaserin + phentermine-HCl |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | Combination weight-loss agent (5-HT2C agonist + sympathomimetic amine) |
| Target | 5-HT2C receptor (lorcaserin); norepinephrine release (phentermine) |
| Modality | Small molecule |
| Therapeutic area | Obesity/Weight Management |
| Phase | FDA-approved |
Mechanism of action
Lorcaserin selectively activates serotonin 5-HT2C receptors in the hypothalamus to promote satiety and reduce food intake. Phentermine acts as a sympathomimetic agent that stimulates the release of norepinephrine, increasing metabolic rate and appetite suppression. Together, these agents work synergistically to produce greater weight loss than either agent alone.
Approved indications
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Common side effects
- Headache
- Dizziness
- Nausea
- Dry mouth
- Insomnia
- Constipation
- Tachycardia
Key clinical trials
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (PHASE4)
- A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lorcaserin + phentermine-HCl CI brief — competitive landscape report
- lorcaserin + phentermine-HCl updates RSS · CI watch RSS
- Eisai Inc. portfolio CI